{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05693766",
            "orgStudyIdInfo": {
                "id": "VICCBRE2256"
            },
            "organization": {
                "fullName": "Vanderbilt-Ingram Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort",
            "officialTitle": "Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)",
            "acronym": "INSIGHT",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "gene-signatures-to-guide-hr-mbc-therapy-in-a-diverse-cohort"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2037-08-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-11",
            "studyFirstSubmitQcDate": "2023-01-11",
            "studyFirstPostDateStruct": {
                "date": "2023-01-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Sonya Reid",
                "investigatorTitle": "Assistant Professor of Medicine",
                "investigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
            },
            "leadSponsor": {
                "name": "Sonya Reid",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Agendia",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Susan G. Komen Breast Cancer Foundation",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)",
            "detailedDescription": "Primary Objective:\n\n- Determine the impact of early chemotherapy (i.e., capecitabine) versus endocrine therapy-based regimen on anti-tumor effect in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer\n\nSecondary Objectives:\n\n* Compare the safety and tolerability of capecitabine versus endocrine therapy in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer\n* Determine the impact of early chemotherapy (i.e., capecitabine) versus endocrine therapy-based regimen on anti-tumor effect in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer\n\nCorrelatives:\n\n* Determine if the tumor mutations detected in cfDNA are early surrogates of response\n* Determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to therapy"
        },
        "conditionsModule": {
            "conditions": [
                "Invasive Mammary Carcinoma",
                "Metastatic Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 64,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Other: Endocrine-therapy",
                        "Other: MammoPrint \u00ae and BluePrint assays"
                    ]
                },
                {
                    "label": "Capecitabine_Non-Luminal A subtypes",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Capecitabine",
                        "Other: MammoPrint \u00ae and BluePrint assays"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "2000 mg taken by mouth twice daily for 7 days on, 7 days off",
                    "armGroupLabels": [
                        "Capecitabine_Non-Luminal A subtypes"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Endocrine-therapy",
                    "description": "Endocrine therapy administered",
                    "armGroupLabels": [
                        "Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "MammoPrint \u00ae and BluePrint assays",
                    "description": "Archival tissue will be analyzed using the MammoPrint \u00ae and BluePrint assays",
                    "armGroupLabels": [
                        "Capecitabine_Non-Luminal A subtypes",
                        "Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression free survival",
                    "timeFrame": "Up to 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall survival at 2 years",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Overall survival at 5 years",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Overall survival at 10 years",
                    "timeFrame": "Up to 10 years"
                },
                {
                    "measure": "Clinical Benefit Rate",
                    "description": "Percentage of patients without disease progression at 6 months",
                    "timeFrame": "Approximately 6 months"
                },
                {
                    "measure": "Overall response rate",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Incidence of adverse events",
                    "timeFrame": "Up to 28 days post-treatment"
                },
                {
                    "measure": "Overall impact of treatment toxicity",
                    "description": "Will be measured using Functional Assessment of Cancer Therapy (FACT)-G (5 point Likert-type scale from 1 (\"none at all\") to 5 (\"very much\")",
                    "timeFrame": "Up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and dated written informed consent.\n* Subjects \u2265 18 years of age.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence of invasive mammary carcinoma that is:\n\n  * ER (\\>/=1%) and/or PR (\\>/= 1%) by IHC and HER2 negative (by IHC or FISH)\n* Previously exposed to an aromatase inhibitor (AI) or a selective estrogenreceptor modulator/ downregulator (SERM; SERD) + a CDK4/6 inhibitor.\n* Prior radiation permitted (if completed at least 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (\u2264 grade 1) induced by this treatment (except for alopecia)\n* Patients with brain metastasis secondary to breast cancer and clinically stable for more than 4 weeks from completion of radiation treatment and off steroids\n* Evaluable disease (measurable or non-measurable)\n\n  * Measurable disease, ie, at least 1 measurable lesion as per RECIST 1.1 (a lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation)\n  * Patients with bone only disease allowed if possible to evaluate on radiological exams (eg.bone scan, PET/CT, CT, MRI) even if lesions are non-measurable according to RECIST1.1.\n* Adequate organ function including:\n\n  * Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 10\\^9/L\n  * Platelets \u2265 100 \u00d7 10\\^9/L\n  * Hemoglobin \u2265 8/g/dL (may have been transfused)\n  * Total serum bilirubin \u2264 1.5 times upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) \u2264 2.5 \u00d7 ULN (or \u2264 5 \u00d7 ULN if liver metastases are present)\n  * Serum creatinine \u2264 1.5 x ULN or estimated creatinine clearance \u2265 50mL/min as calculated using the Cockcroft-Gault (CG) equation\n* For randomized patients only: tumors must be diagnosed as non-Luminal A using the Blueprint\u00ae and Mammaprint\u00ae tests\n\nExclusion Criteria:\n\n* Prior chemotherapy in the metastatic setting\n* Previous malignant disease other than breast cancer within the last 2 years with associated competing risk, with the exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or low-risk cancers considered curatively treated (i.e. complete remission achieved at least 2 years prior to first dose of study drugs AND additional therapy not required while receiving study treatment).\n* Persisting symptoms related to prior therapy that has not reduced to Grade 1 \\[National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0\\]; however, menopausal symptoms, alopecia, and sensory neuropathy Grade \u2264 2 is acceptable\n* Pregnant or breastfeeding females.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vanderbilt-Ingram Services for Timely Access",
                    "role": "CONTACT",
                    "phone": "800-811-8480",
                    "email": "cip@vumc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sonya Reid, MD",
                    "affiliation": "Vanderbilt University/Ingram Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Vanderbilt University/Ingram Cancer Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vanderbilt-Ingram Service for Timely Access",
                            "role": "CONTACT",
                            "phone": "800-811-8480",
                            "email": "cip@vumc.org"
                        },
                        {
                            "name": "Sonya Reid, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                }
            ]
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-02-16",
                    "uploadDate": "2023-03-28T12:25",
                    "filename": "ICF_000.pdf",
                    "size": 1183380
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Mammary Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}